RecruitingEarly Phase 1NCT07294625

A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec200 Product in the Treatment of Relapsed/Refractory Multiple Myeloma

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment

36 participants

Start Date

Dec 10, 2025

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment called LVIVO-TaVec200 in patients with multiple myeloma (a type of blood cancer) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have multiple myeloma that has returned or is no longer responding to treatment - You are in reasonably good health (able to carry out daily activities) - Your life expectancy is at least 3 months - Your organ function meets the required levels **You may NOT be eligible if...** - You had prior treatment and haven't waited the required washout period - You have previously been treated with a therapy targeting GPRC5D - You have active hepatitis B, hepatitis C, or HIV - You have a history of severe allergic reactions to study drug ingredients Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALLVIVO-TaVec200 product

Prior to infusion of the LVIVO-TaVec200 product, subjects will receive bridging therapy if needed.

Locations(5)

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

The Affiliated Hospital of XUZHOU Medical University

Xuzhou, Jiangsu, China

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07294625

Related Trials

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575273 locations